Aardvark Therapeutics, Inc. AARD 深 滬
等待開盤 09-25 09:30:00 美东时间
12.17
+0.730
+6.38%
華盛通- 最 高12.32
- 今 開11.44
- 成交量 8.74万股
- 最 低 11.44
- 昨 收 11.44
- 總市值 2.64亿
- 52周最高 19.58
- 市盈率 靜 --
- 換手率 0.40%
- 52周最低 4.88
- 委 比 0.00%
- 總股本 2169.69万
- 歷史最高 19.58
- 量 比 0.37
- 振 幅 7.69%
- 歷史最低 4.88
- 每 手 1
- 風險率 2.09%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 升至450美元，瑞穗上调特斯拉目标价；富国银行上调CoreWeave至"超配"，目标价升至170美元
今日重点评级关注：Guggenheim：维持MBX Biosciences"买入"评级，目标价从44美元升至84美元；Oppenheimer：维持MBX Biosciences"跑赢大市"评级，目标价从38美元升至80美元
09-24 10:23
Aardvark Therapeutics to Present at the Stifel 2025 Virtual Cardiometabolic Forum
Aardvark Therapeutics will present at the Stifel 2025 Virtual Cardiometabolic Forum on September 30, 2025, at 9:00 a.m. ET. The presentation will discuss its clinical-stage small-molecule therapeutics for metabolic diseases, including ARD-101, a Phase 3 candidate for Prader-Willi Syndrome, and ARD-201, a combination therapy for obesity. A live webcast and archived recording will be available on the company’s investor website.
09-23 20:05
HC Wainwright & Co. Reiterates Buy on Aardvark Therapeutics, Maintains $40 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Aardvark Therapeutics (NASDAQ:AARD) with a Buy and maintains $40 price target.
09-23 19:15
Schizophrenia drug developer LB Pharma jumps in trading debut
LB Pharmaceuticals (LBRX) climbed ~26% on Thursday as the New York-based biopharma, focused on developing drugs for neurological conditions such as schizophrenia, opened for trading after raising $285...
09-12 01:41
LB Pharmaceuticals(LBRX.US)IPO定价15美元/股 今晚登陆纳斯达克
LB Pharmaceuticals将于周四在纳斯达克上市，股票代码为“LBRX”
09-11 11:53
生物科技IPO“解冻”！LB Pharmaceuticals(LBRX.US)IPO定价14-16美元/股，拟筹资2.5亿美元
LB Pharmaceuticals(LBRX.US)周一公布了IPO定价条款。
09-09 15:04
Aardvark Therapeutics to Present at Upcoming Investor Conferences in September
Aardvark Therapeutics, a clinical-stage biopharmaceutical company, announced it will present at three conferences in September 2025: the Cantor Fitzgerald Global Healthcare Conference, the Morgan Stanley 23rd Annual Global Healthcare Conference, and the H.C. Wainwright 27th Annual Global Investment Conference, all held in New York. Live webcasts of the presentations are accessible on the company’s website, and archived recordings will be availabl...
08-27 20:10
Aardvark Therapeutics Advances Clinical Trials and Financials
Aardvark Therapeutics, Inc. ( ($AARD) ) has released its Q2 earnings. Here is a...
08-27 12:05
Aardvark Therapeutics Q2 EPS $(0.66) Misses $(0.61) Estimate
Aardvark Therapeutics (NASDAQ:AARD) reported quarterly losses of $(0.66) per share which missed the analyst consensus estimate of $(0.61) by 7.67 percent. This is a 51.82 percent increase over losses of $(1.37) per share
08-14 04:24
Aardvark Therapeutics Reports Second Quarter 2025 Financial Results and Provides Pipeline and Business Updates
Aardvark Therapeutics reported $141.8 million in cash to support operations into 2027. Key updates include expanding the Phase 3 HERO trial for PWS to include pediatric patients under 13, and advancing ARD-201 into Phase 2 trials focusing on weight management strategies. The company also announced the initiation of the Phase 2 POWER and STRENGTH trials for ARD-201, targeting weight regain prevention and durable weight loss, respectively. Addition...
08-13 20:10
